Unveiling Massey University's Landmark Study on Feline Heart Disease in New Zealand
Researchers at Massey University's Tāwharau Ora School of Veterinary Science have shed new light on cat heart disease in New Zealand through a comprehensive study published in the New Zealand Veterinary Journal. The investigation focused on hypertrophic cardiomyopathy (HCM), the most prevalent form of feline cardiomyopathy, characterized by the thickening of the heart muscle, particularly the left ventricle, which can impair cardiac function over time. Conducted using a colony of non-purebred cats at the Centre for Feline Nutrition (CFN), the study serves as a proxy for the wider New Zealand domestic cat population, estimated at around 1.26 million pets in 2025. This research not only quantifies the prevalence of subclinical HCM—meaning cases without obvious symptoms—but also assesses cardiac mortality rates, revealing that while the condition is common, it rarely proves fatal.
The study's lead author, Dr. Joon Seo, along with colleagues from Massey and collaborators from the Royal Veterinary College in the UK, employed rigorous methods including echocardiography and post-mortem examinations. Their findings challenge assumptions about feline heart health and underscore the importance of ongoing veterinary research in higher education institutions like Massey University, New Zealand's premier veterinary school.
What is Hypertrophic Cardiomyopathy in Cats?
Hypertrophic cardiomyopathy (HCM) is defined as a primary myocardial disorder where the heart muscle walls, especially in the left ventricle, become abnormally thickened (≥6 mm in cats), reducing the chamber size and potentially hindering blood flow. Unlike secondary forms caused by conditions like hyperthyroidism or hypertension, primary HCM arises from genetic mutations or idiopathic causes. In cats, HCM accounts for over 94% of diagnosed cardiomyopathies in apparently healthy individuals.
Subclinical HCM means the cat shows no outward signs such as lethargy, rapid breathing, or collapse, yet structural changes are detectable via advanced imaging. Globally, prevalence in screened healthy cats hovers around 15%, increasing with age—up to 29.4% in seniors. In New Zealand, prior data was scarce, making this Massey-led effort pivotal. The condition can progress to congestive heart failure, arterial thromboembolism (ATE), or sudden cardiac death, but many cats live normal lifespans without complications.
To diagnose HCM, veterinarians first rule out mimics through blood tests for thyroid levels and blood pressure measurements, then use echocardiography to measure wall thickness, chamber dimensions, and function metrics like fractional shortening.
Study Design and Methodology at Massey University's CFN Colony
The CFN colony, established in 1992, houses 130-150 non-purebred cats sourced from rehoming centers, refreshed every five years to mirror New Zealand's diverse pet population. From 2012 to 2022, researchers screened 132 adult cats (median age 4.1 years) via physical exams, cardiac auscultation for murmurs or gallops, and targeted echocardiography on those with abnormalities. No sedation was used, employing a 4.4–6.2 MHz probe for 2D imaging.
For mortality analysis, all 168 colony deaths underwent review, with 132 receiving full necropsies by veterinary pathologists. Cardiac death was attributed if evidence of heart failure, thromboembolism, or gross/microscopic cardiac lesions existed without overriding non-cardiac causes. Statistical analysis used SPSS to compute proportions and 95% confidence intervals (CI). This prospective prevalence and retrospective mortality approach provided robust, real-world data reflective of typical Kiwi cats.
Key Prevalence Findings: Subclinical HCM is Widespread
Echocardiography detected heart disease in 18.2% (24/132) of screened cats, with 17.4% exhibiting HCM phenotype initially. After excluding three cases due to hypertension or hyperthyroidism, confirmed subclinical HCM stood at 15.2% (20/132 cats; 95% CI 9.5–22.4%). Notably, only 24% had audible heart murmurs and 2% arrhythmias, highlighting that clinical exams alone miss most cases.
- Left ventricular wall thickness averaged higher in HCM cats.
- One cat had restrictive cardiomyopathy (RCM), a rarer form.
- Prevalence aligns with international figures (10-15%), suggesting similar burden in NZ.
Extrapolating to NZ's 1.2-1.26 million cats implies 114,000-190,000 with subclinical HCM, emphasizing public health relevance for pet owners.
Cardiac Mortality: Low Risk Despite High Prevalence
Among 132 necropsied cats (median lifespan 11.3 years), 28% showed cardiac abnormalities, yet only 5.3% (7/132; 95% CI 2.2–10.6%) died from heart disease: five HCM, one congenital defect, one myocarditis. HCM-specific mortality was 3.8% (5/132; 95% CI 1.2–8.6%). Remarkably, 22.7% had incidental cardiac findings but succumbed to non-cardiac issues like cancer or infection.
This low fatality rate (far below the 63.4 per 1,000 cat-years in diagnosed HCM cohorts) indicates many subclinical cases stabilize or progress slowly. Older age at death versus screening explains higher necropsy abnormalities.
Photo by Sean Foster on Unsplash
Implications for Cat Owners and Vets in New Zealand
With 40% of Kiwi households owning cats amid 63% pet ownership rates, this study urges proactive screening, especially pre-anesthesia, steroid therapy, or fluid administration where HCM risks complications. Vets should discuss echocardiography for breeds like Sphynx (40% HCM prevalence in a companion Massey study) or seniors over 9 years.
Owners can monitor for subtle signs:
- Persistent heart murmurs on routine checks.
- Exercise intolerance or rapid respiration.
- Sudden hindlimb paralysis (ATE).
For more on veterinary careers supporting such research, explore higher education jobs at institutions like Massey.
Read the full study here.
Sphynx Cats: A High-Risk Breed in NZ Context
A parallel Massey study on 55 Sphynx cats found 21.8% HCM at baseline, rising to 40% at median 5.8 years, with ALMS1 variant in 70.9% but no direct link. Three HCM cats died from myocardial infarction, underscoring breed predisposition despite screening. Breeders should prioritize serial echoes, as HCM can emerge post-initial clears.
Global Comparisons and NZ Uniqueness
NZ findings mirror UK/US prevalences (15%), but low mortality may reflect colony health management or genetic factors in non-purebreds. Unlike purebred-heavy studies, NZ's mixed population offers valuable insights. Ongoing Oriental cat research at Massey promises further breed data.
Check Healthy Pets NZ summary here.
Diagnostic Advances and Screening Recommendations
Echocardiography remains gold standard, measuring interventricular septum and posterior wall thickness. Emerging tools like strain imaging detect early dysfunction. NZ vets follow international guidelines: annual screens for at-risk breeds from age 1 year. Massey's courses in small animal echocardiography train vets accordingly.
Treatment, Management, and Prognosis
Subclinical HCM often needs no treatment, just monitoring. Symptomatic cases use beta-blockers (atenolol), calcium channel blockers (diltiazem), or diuretics for failure. Antithrombotics like clopidogrel prevent ATE. Prognosis varies: subclinical often excellent; advanced poor. Lifestyle: low-stress environments, controlled diet.
- Step 1: Confirm diagnosis, exclude secondaries.
- Step 2: Stage via echo (mild/moderate/severe).
- Step 3: Tailor therapy, recheck 3-6 months.
Massey University's Leadership in Veterinary Research and Education
Massey's vet school leads NZ feline cardiology, offering BVSc programs with hands-on clinic rotations in cardiorespiratory medicine. This study exemplifies student involvement in publishable research, fostering careers in academia. Aspiring lecturers can find lecturer jobs here, while NZ university jobs abound in vet science.
Future Outlook: Ongoing Research and Prevention
Pending Oriental cat results and genetic studies may refine risks. Genetic testing expands, alongside AI-enhanced echoes. Public awareness campaigns could boost screening rates. For career advice in vet research, visit higher ed career advice.
In summary, while subclinical cat heart disease affects 10-20% of NZ cats, low fatality reassures owners, but vigilance saves lives. Connect with rate my professor for insights on top vet educators.
